Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 9/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8138003 | 0.91 | GSK3B (0.54) | GSK3BGABRA2GABRB2DPP4DPP8 | |
| SCHEMBL8143251 | 0.80 | GSK3B (0.45) | GSK3BMAPT | |
| SCHEMBL2935927 | 0.79 | GSK3B (0.45) | GSK3BHPGD | |
| SCHEMBL1514107 | 0.79 | GSK3B (0.81) | GSK3BGABRA2GABRB2DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL1514015 | 0.78 | GSK3B (0.45) | GSK3BDPP4MAPT | |
| SCHEMBL12680888 | 0.78 | ADORA2A (0.40) | GSK3BGABRA2GABRB2DPP4DPP8 | |
| SCHEMBL1514100 | 0.78 | GSK3B (0.75) | GSK3BGABRA2GABRB2DPP4DPP8 | |
| SCHEMBL1513972 | 0.74 | GSK3B (0.52) | GSK3BGABRA2GABRB2DPP4DPP8 | |
| SCHEMBL12835580 | 0.73 | GSK3B (0.71) | GSK3BDPP4 | |
| SCHEMBL8039872 | 0.73 | GSK3B (0.39) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434731-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20130261115-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-03 | — | — | US | disclosed |
| US-8476267-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| EP-2176264-B1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES FOR TREATING HEMATOLOGICAL DISORDERS | BAYER IP GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053929-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053929-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | THPO, TPMT, IKZF3 | GSK3B 4433/4885GABRA2 1064/4885GABRB2 2451/4885 |
| US-20130261115-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | THPO, TPMT, IKZF3 | GSK3B 4433/4885GABRA2 1064/4885GABRB2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.